Dr. Burger on Bevacizumab in Ovarian Cancer

Robert A. Burger, MD
Published: Wednesday, Oct 09, 2013

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

There were two phase II trials of monotherapy bevacizumab that demonstrated significant activity in the recurrent setting of ovarian cancer and nearly equivalent activity in platinum-resistant and platinum-sensitive disease. At the same time, Burger says, bevacizumab was approved by the FDA for the treatment of metastatic colorectal cancer and non-small cell lung cancer, so it was commercially available. When data were initially presented in this space, the use of bevacizumab in the recurrent setting was already fairly widespread.

In fact, Burger says, when phase III trials were initiated for patients with ovarian primary peritoneal and fallopian tube cancer, most patients were receiving bevacizumab in the recurrent disease setting. Burger goes on to say that the data from phase III trials, which showed significant prolongation in progression-free survival, and previous phase II monotherapy trials, were enough to generate interest in the off-label use of bevacizumab in the frontline.

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

There were two phase II trials of monotherapy bevacizumab that demonstrated significant activity in the recurrent setting of ovarian cancer and nearly equivalent activity in platinum-resistant and platinum-sensitive disease. At the same time, Burger says, bevacizumab was approved by the FDA for the treatment of metastatic colorectal cancer and non-small cell lung cancer, so it was commercially available. When data were initially presented in this space, the use of bevacizumab in the recurrent setting was already fairly widespread.

In fact, Burger says, when phase III trials were initiated for patients with ovarian primary peritoneal and fallopian tube cancer, most patients were receiving bevacizumab in the recurrent disease setting. Burger goes on to say that the data from phase III trials, which showed significant prolongation in progression-free survival, and previous phase II monotherapy trials, were enough to generate interest in the off-label use of bevacizumab in the frontline.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x